Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab with etoposide and a platinum-based compound within its marketing authorisation for untreated extensive-stage small-cell lung cancer
 
Status In progress
Process STA 2018
ID number 1509

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 05 December 2019 - 10 January 2020
Committee meeting 07 October 2020
Expected publication 16 December 2020

Project Team

Project lead Louise Jafferally

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 December 2019 Consultation on the draft scope and provisional matrix of consultees and commentators, with comments requested by 10 January 2020.
08 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Following an update from the company further information on the timelines for this appraisal will be available in due course.
22 March 2019 In progress, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- July 2019 when we will write to you about how you can get involved.
14 November 2018 - 12 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance